Physician profile
Grace Chiang
NPI 1750556106
$5,286.10
in general payments reported to CMS, 2019-2025
24 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $524 · 2021: $1,016 · 2022: $796 · 2023: $684 · 2024: $545 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,479 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,479.18 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,053.27 | 2021-2025 | |
| Glaxosmithkline, LLC. | $934.42 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $535.51 | 2020-2025 | Dupixent |
| Optinose US, INC. | $435.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $420.20 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $265.26 | 2021-2025 | Tezspire |
| Covis Pharma Gmbh | $215.00 | 2020-2022 | |
| Genentech USA, INC. | $167.10 | 2019 | |
| Grifols USA, LLC | $166.99 | 2021-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $166.80 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Novartis Pharmaceuticals Corporation | $156.12 | 2019-2025 | |
| Alk-Abello, INC | $119.27 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Pfizer INC. | $103.85 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $70.41 | 2020-2022 | |
| Abbvie INC. | $70.36 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.33 | 2019-2021 | |
| Kaleo, INC. | $64.69 | 2020-2023 | Auvi-Q |
| Pharming Healthcare, INC. | $53.73 | 2020-2025 | Ruconest |
| Lilly USA, LLC | $45.24 | 2025 | Ebglyss |
| Blueprint Medicines Corporation | $42.97 | 2025 | Ayvakit |
| Organon LLC | $39.63 | 2025 | Vtama, Nexplanon |
| Leo Pharma INC. | $35.97 | 2022 | |
| Shire North American Group INC | $33.57 | 2019 | |
| Aimmune Therapeutics, INC. | $19.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Chiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.